Galytx

Galytx is at the forefront of biotechnology research, driving innovation in Galectin-3 targeted therapeutics to address major unmet clinical needs in cancer and fibrosis. Galytx is dedicated to developing novel therapeutics that specifically target galectin-3, a clinically relevant molecular target in cancer, fibrosis, and inflammation.

Overexpression of galectin-3 is a significant driver of morbidity and mortality in these diseases, and Galytx is pioneering a unique portfolio of first-in-class, non-carbohydrate, wholly synthetic small molecule assets to address this critical need. With a pipeline that includes both clinical and pre-clinical assets, Galytx is poised to make a significant impact on patient outcomes. The primary address of Galytx is Brownlow Hill, Foundation Building, Liverpool, L69 3BX, GB.

Galytx's lead clinical asset is a repurposed drug with a strong and well-established safety record in chronic oral use, enabling a fast-track clinical development pathway. Their pre-clinical assets are being developed to produce high-potency injectable therapeutics for acute use. Galytx is initially focusing on triple-negative breast cancer and chronic heart failure, with a vision to extend its reach to address the full spectrum of galectin-3-mediated pathologies. We invite the management of Galytx to create a customized and exclusive company showcase and product listing on our platform to further enhance their commercial development.